(Nasdaq: SINT) Guides Toward Potential Revenue Step-Up After $3.2Mn In New Orders

Walk into almost any orthopedic operating room

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: SINT) Guides Toward Potential Revenue Step-Up After $3.2Mn In New Orders *Get Our Updates Faster—Tap Here To Receive SMS Alerts* September 30th Greetings, Friend! Walk into almost any orthopedic operating room and the implant menu looks familiar: titanium, PEEK, and a short list of long-established options. So it caught our attention when Orthopedics This Week, the industry’s most widely read publication, released a Masterclass in mid-September built around a material most surgeons have never placed: silicon nitride. The sponsor behind it is SINTX Technologies, Inc. (Nasdaq: SINT), a Salt Lake City company that points to three decades of silicon nitride leadership. The program brings together experts in implant retrieval, biomaterials, and clinical practice to weigh silicon nitride against PEEK and titanium. The Masterclass followed a busy summer. The company’s mid-year business update disclosed roughly $3.2Mn in new industrial purchase orders from multiple contract manufacturing customers, with initial shipments already underway. Management now expects approximately $0.9Mn to $1.1Mn in Q3 2026 revenue and approximately $1.0Mn to $1.3Mn in Q4. That outlook stands out against the $452K in revenue reported for Q2 2026. At the midpoint, Q3 guidance would be more than twice the prior quarter, though the company cautions that purchase-order value does not assure revenue timing. Wall Street is watching. H.C. Wainwright reiterated a $10 target in mid-August, Maxim Group reiterated in May with a $6.00 target, and Ascendiant Capital Markets pegged a $12.00 target in April. Each target points to potential triple-digit upside from Wednesday’s SINT close. About SINTX Technologies, Inc. SINTX develops, manufactures and commercializes silicon nitride biomaterials, composites and devices for medical and other high-value applications. The company cites the material’s demonstrated bone affinity and inherent resistance to bacterial adhesion as its clinical edge. Revenue runs through two channels. The medical side centers on the FDA 510(k)-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System, now in a Limited Use Release supported by twelve independent foot-and-ankle distributors. The industrial side produces advanced ceramic components for contract manufacturing customers, a base management says helps fund its medical programs. Recent moves shaped today’s structure. SINTX completed its acquisition of SiNAPTIC Surgical, then named Ryan Elmore President in March 2026, the same month surgeons performed the first human procedure with the wedge system. It also finished a 3D printing facility for SiNERGY™ patient-specific implants. The target market is sizable: Research and Markets values foot and ankle devices at $7.3Bn in 2026, with a forecast of $10.77Bn by 2030. Additional Sources And More: SINT Website. SINT Presentation. Foot and ankle devices market outlook. Source: Research and Markets. View source. Behind The Scenes: What Management Is Telling The Street In the August update, SINTX Chairman and CEO Eric K. Olson framed the story as bigger than one implant. “Our strategy has always extended well beyond the introduction of a single medical device,” he said, pointing to new commercial infrastructure, manufacturing capacity and strategic relationships. President Ryan Elmore carried that message into the Masterclass, calling education “an important part of introducing innovative biomaterials” to surgeons and highlighting OTW’s reach of more than 400,000 annual readers in over 120 countries. Management also took the story to New York, presenting at H.C. Wainwright’s 28th annual global conference. The Pivot: From Materials Lab To Commercial Engine The mid-year update frames a transition from technology development toward commercial execution, and the revenue guidance below is where that transition becomes measurable. Q2 reported revenue vs. company guidance for Q3 and Q4 2026. View source. Licensing is next in line. Animal studies of the company’s antipathogenic suture and wound care technologies were scheduled to begin in Q3 2026, with preliminary data targeted for potential licensing partners before year-end. About $5.0Mn in gross proceeds raised in Q2, plus a cost optimization program, supports the rollout. 6 Potential Catalysts Putting (Nasdaq: SINT) At The Top Of Our Watchlist #1. Company Guidance Points To A Potential Revenue Step-Up. If delivered, management’s Q3 outlook would mark a sharp climb from Q2 for SINTX (SINT). #2. Roughly $3.2Mn In Industrial Orders Already Shipping. Initial shipments have begun, giving SINTX (SINT) visible revenue as recognition starts in Q3 2026. #3. Low Float Setup Could Mean Heightened Volatility. Yahoo Finance lists a float under 6Mn shares, making (SINT) a low float idea where the potential for heightened volatility may be significant. #4. Analyst Targets Sit Well Above Recent Chart Positioning. H.C. Wainwright, Maxim Group and Ascendiant all carry significant (SINT) targets ranging from $6 to $12. #5. Preliminary Animal Data Could Fuel Licensing Talks. Suture and wound care data targeted for potential partners before year-end could be an inflection point for SINTX (SINT). #6. FDA-Cleared Implant Expanding Through Twelve Specialized Distributors. The SiNAPTIC Limited Use Release gives SINTX (SINT) a live commercial channel in foot and ankle surgery. Final Take: Why (Nasdaq: SINT) Is On Our Radar SINTX Technologies, Inc. (Nasdaq: SINT) spent years proving a material. The story now is whether that material can move through distributors, purchase orders and partner labs at scale. The coming months bring measurable checkpoints: Q3 results against guidance, with the next report expected around November 11th, 2026, plus animal data headed to potential licensing partners. For readers tracking where advanced materials meet orthopedic care, Sintx Technologies, Inc. is a name to keep on your radar and review closely in the weeks ahead. Coverage is now underway on SINTX Technologies, Inc. (Nasdaq: SINT). Be on the lookout for updates heading out soon. We’ll be in touch. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 09/30/2026 and ending on 10/01/2026 to publicly disseminate information about (SINT:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the ninety thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (SINT:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/sint-l7xjj/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Constant Contact Data Notice